Evaluation of the lipid lowering ability, anti-inflammatory effects and clinical safety of intensive therapy with Zhibitai, a Chinese traditional medicine.
OBJECTIVE
To evaluate the lipid lowering ability, anti-inflammatory effects and clinical safety of intensive therapy of the Chinese traditional medicine Zhibitai in subjects with moderate to high cardiovascular risk.


METHODS
A total of 169 subjects (96 males and 73 females, aged 55-72) having moderate to high cardiovascular risk were recruited and randomly divided into Zhibitai group (n=85), which received 480 mg of Zhibitai orally twice daily, and atorvastatin group (n=84), which received 10 mg of atorvastatin orally once a day. Blood lipoproteins, myocardial enzymes, liver and renal functions were measured before treatment started, and after 4 and 8 weeks of the treatment. High sensitivity C-reactive protein (hs-CRP), P-selectin, matrix metalloproteinase-9 (MMP-9) and soluble intercellular adhesion molecule-1 (sICAM-1) were measured before and after the treatment.


RESULTS
Plasma total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) were significantly decreased, and high-density lipoprotein cholesterol (HDL-C) was increased in both groups, after 4 and 8 weeks of treatment (p<0.05 for all pairs). Interestingly, plasma triglycerides (TG) decreased in the Zhibitai group after 4 weeks of treatment but only decreased in the atorvastatin group after 8 weeks. Inflammatory factors such as hs-CRP, P-selectin, MMP-9 and sICAM-1 were significantly decreased in both groups after 8 weeks (p<0.01 for all pairs). Furthermore, there was no difference in myocardial enzymes, hepatic and renal function test parameters, incidence of myopathy or gastrointestinal tract symptoms in either group.


CONCLUSIONS
Zhibitai therapy is a good alternative to statin therapy to reduce plasma cholesterol levels in subjects with moderate to high cardiovascular risk. Most importantly, Zhibitai is safe to use.
Xu
Dan-yan
DY
Department of Internal Cardiovascular Medicine, Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, PR China. xudanyan02@sina.com
Shu
Jun
J
Huang
Quan-yue
QY
Wasti
Binaya
B
Chen
Chen
C
Liu
Ling
L
Zhao
Shui-ping
SP
D000368:Aged; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D000069059:Atorvastatin; D002097:C-Reactive Protein / Q000378:metabolism; D002784:Cholesterol / Q000097:blood; D004365:Drugs, Chinese Herbal / Q000627:therapeutic use*; D005260:Female; D006538:Heptanoic Acids / Q000627:therapeutic use*; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy*; D018799:Intercellular Adhesion Molecule-1 / Q000097:blood; D008297:Male; D020780:Matrix Metalloproteinase 9 / Q000097:blood; D008516:Medicine, Chinese Traditional; D008875:Middle Aged; D019007:P-Selectin / Q000097:blood; D011758:Pyrroles / Q000627:therapeutic use*; D014280:Triglycerides / Q000097:blood
D000893:Anti-Inflammatory Agents; D000924:Anticholesteremic Agents; D004365:Drugs, Chinese Herbal; D006538:Heptanoic Acids; D019007:P-Selectin; D011758:Pyrroles; D014280:Triglycerides; C553042:zhibitai; D018799:Intercellular Adhesion Molecule-1; D002097:C-Reactive Protein; D002784:Cholesterol; D000069059:Atorvastatin; D020780:Matrix Metalloproteinase 9